Scientists crack genetic code of liver fluke parasite

Singapore-An international team of scientists from Singapore, Thailand, China and Australia has cracked the genetic code of the liver fluke parasite, Opisthorchis viverrini, using a unique DNA analysis technique developed at A*STAR's Genome Institute of Singapore (GIS).

GIS's DNA analysis technique has allowed the researchers to further study the biology of Opisthorchis viverrini to understand the cause and the eventual development of treatments for bile duct cancer, a condition caused by the parasite. The breakthrough was published in the scientific journal Nature Communications.

Opisthorchis viverrini is a trematode that infects millions in Asia, and it is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). It is also a significant risk factor for Cholangiocarcinoma (CCA) or bile duct cancer. This parasite is endemic to some countries in Southeast Asia including Northeastern Thailand, Laos and Cambodia, with only 96 per 100,000 cases being reported in these countries. Despite its prevalence, there is no vaccine and only one drug (praziquantel) available to counter the parasitic worm.

The fluke enters the human body through the ingestion of raw or undercooked contaminated fish. Once in the small intestines, the worm migrates to the liver's bile ducts, where it lodges, feeds and matures. It is not known for certain how the fluke causes cancer. One widely accepted hypothesis is that the fluke secretes a protein mimicking the human growth hormone, granulin, which is extremely potent at stimulating cell growth and proliferation and is therefore highly regulated in the body. Infected individuals however, are constantly exposed to granulin-like proteins secreted by flukes, which subsequently cause host cells to proliferate uncontrollably, leading to tumour growth.

By mapping out the genes of this parasite, researchers aim to better understand its molecular pathways. This will help them identify new biological markers which could potentially be developed into powerful diagnostic tools and effective treatments for parasite-specific diseases.

This research was part of an international collaboration involving team leads, Dr Niranjan Nagarajan and Professor Patrick Tan from Sinagpore's GIS, and Dr Neil Young and Professor Robin B. Gasser from Australia's University of Melbourne, and others from Thailand and China.

"This study gives deep new insights into the life of a parasitic fluke in the human bile duct, and was enabled by the development of an exciting new genome assembly tool called OPERA-LG in our lab. It has allowed us to assemble and characterise the largest parasitic worm genome studied to date," said Dr Niranjan Nagarajan.

Professor Tan added, "This work builds on our earlier work to complete the picture of host and pathogen genetics of cholangiocarcinoma. These new genomic resources provide a foundation for systems biology investigations of host-pathogen interactions, with a view to uncovering new treatment strategies."

"GIS is constantly developing new genome analytic techniques to realise the huge potential of genomics in finding future cures. The success in sequencing the genome of the liver fluke is a testament of our capabilities to help scientists take their research a level up towards medical discovery," said Professor Ng Huck Hui, Executive Director of GIS.

Source: Biomedical Sciences Institutes (BMSI)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients